Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 vaccine + IMT504
- Development stage
- Preclinical
- Lead developer
- Curative Biotechnology
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This next-generation COVID-19 vaccine candidate, developed by Curative Biotechnology, is a combination of a proprietary protein-based antigen and the IMT504 adjuvant. IMT504 is a non-CpG oligodeoxynucleotide (ODN) that acts as an immunostimulant by targeting and activating B cells and plasmacytoid dendritic cells (pDCs), thereby enhancing the vaccine-induced immune response. The vaccine is specifically designed for immunocompromised patients with kidney failure, including those on dialysis or awaiting kidney transplantation, who typically exhibit poor responses to standard mRNA-based COVID-19 vaccines. Curative Biotechnology licensed the IMT504 technology from Mid-Atlantic BioTherapeutics for this indication.
- Other names
- IMT504-adjuvanted COVID-19 vaccineIMT-504-adjuvanted COVID-19 vaccineIMT 504-adjuvanted COVID-19 vaccineCOVID Vaccine with IMT504 Adjuvant
02
Targets
SARS-CoV-2 spikeTLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on COVID-19 vaccine + IMT504.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 vaccine + IMT504.